$9.600
-0.108 (-1.13%)收盘时
OPTN 资讯
OPTN 事件
Paratek Pharmaceuticals completes acquisition of Optinose
Paratek Pharmaceuticals, announced that the Company has completed its acquisition of Optinose. This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA, and Optinose's product XHANCE. Under the terms of the merger agreement, Paratek acquired all outstanding shares of Optinose for approximately $330M, including the assumption of debt and assuming full payment of the contingent value rights, and Optinose shareholders were paid $9 per share in cash and received CVRs for up to $5 per share in cash payable in the event that certain net revenue milestones are achieved by XHANCE. Paratek will pay $1 per share if XHANCE achieves $150M in net sales in any calendar year prior to December 31, 2028, and $4 per share if XHANCE achieves $225M in net sales in any calendar year prior to December 31, 2029. Optinose shareholders approved the merger proposal at Optinose's special meeting of shareholders held on May 16, 2025, and following completion of the merger Optinose's common stock will be delisted from the Nasdaq Global Select Market. The transaction was financed with capital from Paratek, B-FLEXION Life Sciences, and Novo Holdings, and debt financing from funds managed by Oaktree Capital Management.
Optinose reports Q4 EPS (3c) vs ($1.33) last year
Reports Q4 revenue $22.418M, consensus $20.82M.
Optinose downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Optinose to Neutral from Buy with a $9 price target after Paratek Pharmaceuticals announced it will be acquiring the company for $9 per share up front and contingent value rights worth up to $5 per share.
Optinose downgraded to Hold from Buy at Lake Street
Lake Street downgraded Optinose to Hold from Buy with a price target of $9, down from $17, after Paratek Pharmaceuticals announced it will be acquiring OptiNose for up to $330M, or $14 per share. Shareholders will be granted contingent value rights worth up to $5 per share, notes the analyst, who expects no additional bids and for the deal to close in mid-2025.
Paratek Pharmaceuticals to acquire Optinose in $330M transaction
Paratek Pharmaceuticals (PRTK) and Optinose (OPTN) announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, including its approved product Xhance. The transaction value is up to $330M, with consideration payable to shareholders of up to $14 per share, including the payment of contingent value rights tied to future commercial milestones. Over the past 15 months, Paratek has significantly expanded its primary care field force to have a national footprint. Under the terms of the agreement, Paratek will acquire all of Optinose's outstanding shares for $9 per share in cash, plus up to $5 per share in CVRs payable in the event that certain net revenue milestones are achieved by Xhance. Pursuant to the CVRs, Paratek would pay $1 per share if Xhance achieves $150M in net sales in any calendar year prior to December 31, 2028, and $4 per share if Xhance achieves $225M in net sales in any calendar year prior to December 31, 2029. The upfront consideration of $9 per share represents a 50% premium to Optinose's closing trading price on March 19. The transaction will be financed with capital from Paratek, B-Flexion Life Sciences, and Novo Holdings, and debt financing from funds managed by Oaktree Capital Management. The boards of both Paratek and Optinose have unanimously approved the transaction. It is expected to close as early as mid-2025, subject to customary closing conditions, including approval by Optinose shareholders and receipt of required regulatory clearances, if applicable. Upon completion, Optinose's common stock will be delisted from the Nasdaq Global Market.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。